Concord Biotech Navigates Challenges, Eyes Stronger Growth Ahead

Concord Biotech Limited recently unveiled its Q3 and 9-month FY26 earnings, painting a picture of a company strategically positioning itself for future growth amidst a challenging operating environment. While the third quarter showed a robust 14% year-on-year revenue growth, reaching INR 278 crores, the cumulative 9-month period experienced a 5% decline in revenues to INR 729 crores. This dip was primarily attributed to external headwinds faced in the first half of the fiscal year, including global trade uncertainties, regulatory delays, and geopolitical tensions impacting Middle East tenders.

Despite the 9-month revenue contraction, the company's API segment demonstrated resilience and strength, growing by an impressive 24% year-on-year in Q3 FY26. This growth was largely volume-led, indicating sustained market share gains and robust demand for its fermentation-based Active Pharmaceutical Ingredients. The formulation business, however, saw a 14% decline in Q3 FY26 revenue, partly because some opportunities were captured through API sales. Management expressed optimism for a stronger Q4, citing improved order momentum and advanced discussions for second-source supply and CDMO partnerships.

Concord Biotech's profitability for the period was notably impacted by strategic investments. EBITDA margins for Q3 FY26 stood at 35.6%, down from 40.1% in Q3 FY25. This compression was attributed to start-up costs associated with the commercialization of its new injectable facility (Unit 4) and expenses incurred in setting up Stellon Biotech Inc., its US subsidiary. Excluding these one-off costs, the normalized EBITDA margins would have been approximately 40%. The management anticipates that these margins will gradually normalize as the new injectable business scales up.

On the strategic front, Concord Biotech achieved two significant milestones. The company received WHO-GMP certification for its injectable facility, Unit 4, which is a crucial step for entering the domestic Indian market with its own-brand products and pursuing contract development opportunities. This facility is projected to have a peak revenue potential of INR 600 crores, establishing it as a long-term growth platform. Concurrently, the establishment of Stellon Biotech Inc. in the US marks a direct commercial footprint, enhancing marketing, distribution, and commercialization capabilities in a key global market.

The company is also actively pursuing second-source and CDMO opportunities, leveraging improved clarity on US tariff dynamics and progress on the India-EU trade deal. These developments are expected to translate into higher order inflows and increased engagements. Furthermore, Concord Biotech plans to launch two new products in the anti-infective segment this year, strategically targeting large volumes, niche positioning, and limited competition. These initiatives, combined with a robust R&D pipeline of over 10 products across oncology, anti-infectives, and anti-fungal segments, underscore the company's commitment to innovation and market expansion.

Concord Biotech maintains a strong financial position, operating as a zero-debt company with a healthy cash balance of approximately INR 350 crores as of December 31, 2025. This liquidity provides the flexibility to pursue both organic and inorganic growth opportunities. The management expects FY26 growth to be below historical averages due to H1 challenges but anticipates a normalization in performance to historical averages (around 18% CAGR) from FY27 onwards. With the injectable and CDMO segments expected to contribute significantly, the company projects an overall CAGR of 25% once these growth drivers reach full capacity.

Concord Biotech's Q3 and 9-month FY26 performance reflects a period of strategic investment and adaptation. Despite short-term headwinds impacting overall growth and margins, the company's proactive measures in securing regulatory approvals, expanding its global footprint, and developing a robust product pipeline position it for sustained long-term growth and enhanced market leadership.